Autopsy report · NCT01198626

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

“Enrollment would not have been met prior to the end of the pneumonia season. Termination is based on slow enrollment and not related to safety or efficacy.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 1 year before it stopped.
• 32 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Furiex Pharmaceuticals, Inc

Sponsor type

Industry

Conditions

Community-Acquired Bacterial Pneumonia (CABP)

Interventions

JNJ-32729463; moxifloxacin; JNJ-32729463 (Open-Label)

Participants

32

Sites

34

Countries

Canada, Colombia, Germany, Hungary, Poland, United States

Trials that died the same way

• Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting
  “The study was terminated due to study enrollment feasibility and changing needs of non-hospitalized participants. This decision is not based on efficacy or safety concerns.” (64% match in meaning)
• Treatment Resistance Following Anti-cancer Therapies
  “Study terminated due to lack of enrollment that has been compounded by the global COVID-19 pandemic. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.” (64% match in meaning)
• Digital Therapeutic vs Educational App for Depression Among Adolescents
  “Terminated due to difficulty enrolling patients in the proposed time frame” (63% match in meaning)
• Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure
  “The study was stopped due to a very low rate of children with COVID-19 pneumonia that required endotracheal intubation, resulting in no eligible subjects to enroll.” (63% match in meaning)
• Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
  “met minimum enrollment goal, however, enrollment was slow due to the pandemic, therefore, the study was terminated” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.